Edition:
United States

Akers Biosciences Inc (AKR.L)

AKR.L on London Stock Exchange

112.50GBp
8:16am EDT
Change (% chg)

0.00 (+0.00%)
Prev Close
112.50
Open
112.50
Day's High
--
Day's Low
--
Volume
812
Avg. Vol
3,655
52-wk High
255.00
52-wk Low
86.00

Latest Key Developments (Source: Significant Developments)

Akers Biosciences reports 10 pct fall in Q1 revenue
Tuesday, 16 May 2017 07:00am EDT 

May 16 (Reuters) - Akers Biosciences Inc -:Akers Biosciences announces Q1 2017 earnings.Q1 revenue fell 10 percent to $667,300.Qtrly total revenue $667,250 versus $738,023.Akers Biosciences Inc - expect to see growth in flagship pifa heparin pf/4 rapid assay product line for the year.  Full Article

Akers Biosciences reports earnings for fiscal year 2016
Tuesday, 11 Apr 2017 07:00am EDT 

Akers Biosciences Inc : Akers Biosciences reports earnings for fiscal year 2016 .Akers Biosciences - Expect 2017 to be characterized by further growth in flagship PIFA Heparin PF/4 rapid assay product line, sales of rapid cholesterol test.  Full Article

Empery Asset Management reports 8.45 pct passive stake in Akers Biosciences
Friday, 7 Apr 2017 02:32pm EDT 

Akers Biosciences Inc :Empery Asset Management LP reports 8.45 percent passive stake in Akers Biosciences Inc, as of March 30, 2017 - sec filing.  Full Article

Akers Biosciences files for non-timely 10-K - SEC filing
Friday, 31 Mar 2017 04:13pm EDT 

Akers Biosciences Inc : Akers Biosciences Inc files for non-timely 10-K - SEC filing .Akers Biosciences Inc - unable to file 10-K due to delay experienced in completing financial statements and other disclosures in the annual report.  Full Article

Akers Biosciences announces a $2 million private placement
Thursday, 30 Mar 2017 04:25pm EDT 

Akers Biosciences Inc : Akers Biosciences announces a $2 million private placement .Akers Biosciences Inc - Akers Bio will issue 1.4 million shares at a price of $1.40 per share.  Full Article

Akers Biosciences reports preliminary unaudited earnings highlights for fiscal year 2016
Thursday, 30 Mar 2017 08:30am EDT 

Akers Biosciences Inc : Akers Biosciences reports preliminary unaudited earnings highlights for fiscal year 2016 .Akers Biosciences Inc - "expect 2017 to be characterized by further growth in our flagship PIFA heparin PF/4 rapid assay product line".  Full Article

Akers Biosciences allowed U.S. patent for Akers Wellness tests cartridge
Thursday, 16 Feb 2017 07:00am EST 

Akers Biosciences Inc - : US patent,trademark office allowed patent covering akers bio's proprietary cartridge for optical scanning device .Akers Wellness intends to start marketing oxichek™ through direct-to-consumer channels during 2017.  Full Article

Akers Biosciences files for potential stock shelf, size not disclosed
Wednesday, 16 Nov 2016 02:37pm EST 

Akers Biosciences Inc :Files for potential stock shelf; size not disclosed - sec filing.  Full Article

Akers Biosciences reports Q3 earnings
Monday, 14 Nov 2016 07:00am EST 

Akers Biosciences Inc :Akers Biosciences announces Q3 earnings.  Full Article

Akers Biosciences settles, to sell breath technology tests
Friday, 19 Aug 2016 05:19pm EDT 

Akers Biosciences Inc : Settles dispute with Chube, Thirty Six Strategies Llc , Gavin Moran, Frank Runge - SEC Filing .Co can sell all of breath technology tests worldwide, unencumbered by past or future claims by Chube under licensing agreement.  Full Article

More From Around the Web

BRIEF-Akers Biosciences reports earnings for fiscal year 2016

* Akers Biosciences - Expect 2017 to be characterized by further growth in flagship PIFA Heparin PF/4 rapid assay product line, sales of rapid cholesterol test Source text for Eikon: Further company coverage: